Prevention Beyond the Pipeline | Alzheimer's Drug Discovery Foundation - 0 views
-
MiamiOH OARS on 19 Jun 20The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Specifically, the Prevention Beyond the Pipeline RFP supports: * Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA) * Comparative Effectiveness Research: Methods may include randomized trials or epidemiology. * Studies of Cognitive Decline and Cognitive Reserve: Methods may include epidemiology or clinical trials. Current target areas of interest include: - Epigenetics - Inflammation - Mitochondria & metabolic function - Neuroprotection - Proteostasis - Synaptic activity and neurotransmitters - Vascular function - Other aging targets (e.g. senescent cells) - Other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to age-related cognitive decline or dementia risk